Cost-effectiveness of integrated pharmaceutical care in community-based patients with chronic obstructive pulmonary disease
10.3760/cma.j.issn.1671-7368.2012.07.015
- VernacularTitle:社区慢性阻塞性肺疾病患者全程化药学服务的成本-效果分析
- Author:
Zongjun FANG
;
Zhen LI
;
Mingjian GE
;
Rong YANG
;
Ya ZHU
- Publication Type:Journal Article
- Keywords:
Pulmonary disease,chronic obstructive;
Pharmaceutical services;
Economies,pharmaceutical
- From:
Chinese Journal of General Practitioners
2012;(7):507-510
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analyze the cost-effectiveness of integrated pharmaceutical care (IPC) in community-based patients with chronic obstructive pulmonary disease (COPD).Methods The COPD patients were divided randomly into intervention group (group A,n =79) and control group (group B,n =71).Group A received the IPC intervention measures,including serial lectures of pharmaceutical knowledge,home supervision and web-based communications for while group B group had none.Results As compared with group B,group A obviously improved on the knowledge of pharmaceutical treatment effect and side effect (95.1％,67.4％ vs.63.1％,21.9％,x2 =12.445,P=0.000 vs.x2 =55.557,P=0.000).There were notable differences between two groups [ ( 1.77 ± 1.23 ) vs.( 2.42 ± 1.66 ) s,t =2.583,P=0.011],pulmonary rales [ (0.01 vs.0.01)s,Z =2.370,P=0.018],6-min walk distance (6 MWD) [ (457 ± 67 ) vs.(425 ± 72) m,t =2.760,P =0.007 ],vital capacity ( VC ) [ ( 1.60 ± 0.25 ) vs.( 1.49 ± 0.23 ) L,t =2.718,P =0.007 ) ] andquality-of-life items ( 48 ± 10 vs.52 ± 11,t =2.624,P =0.010) after intervention.Analyze of cost-effectiveness show that groupA was superior to group B [ total effect total cost(TE/TC =764.6/4936,15.49％ )vs.(TE/TC =1509.4/4708),32.06％,x2 =6.183,P ＜ 0.01 ].Conclusion IPC can improve the disease condition and achieve excellent cost-effectiveness for community-based COPD patients.
